To include your compound in the COVID-19 Resource Center, submit it here.

Biosimilar Orencia from Momenta and Mylan misses in PK trial

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) and Mylan N.V. (NASDAQ:MYL; Tel Aviv:MYL) said their proposed biosimilar of Orencia

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE